TICKERNERD
Menu
PFEPFEHealthcare · Drug Manufacturers - General

PFE Stock Forecast: Pfizer Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$28
+0.33% on the day

The 28 Wall Street analysts covering Pfizer Inc. hold a median 12-month price target of $28 — +1.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$158.5B
Ticker Nerd rank
82 / 100
Median analyst target
$28
Analysts covering
28
Revenue$15.0B+2.6% y/y
Operating income$3.5B
Net income−$237.0M
Free cash flow$302.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
−3.3%
YTD
+16.0%
1Y
+11.2%
From 52W high
−5.2%
From 52W low
+21.3%
$23
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PFE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pfizer Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Volatility
97
Quality
91
Momentum
79
Accruals
76
Revisions
62
Issuance
51
Growth
39
Size
2

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PFE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PFE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$25$30$35Jan 26Apr 26Jul 26Oct 26PFEHigh $36Median $28Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
10 Buy16 Hold2 Sell
Low $25Median $28High $36

The green dot is the last close — the median target sits +1.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCMaintainsHold$28 → $30
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026GuggenheimMaintainsBuy$35 → $31
13 July 2026BMO CapitalMaintainsOutperform—
13 July 2026BMO CapitalMaintainsOutperform$34 → $30
13 July 2026GuggenheimMaintainsBuy$36 → $35
13 July 2026GuggenheimMaintainsBuy—
10 July 2026B of A SecuritiesMaintainsNeutral$27 → $26
10 July 2026B of A SecuritiesMaintainsNeutral—
8 July 2026JP MorganMaintainsNeutral—
8 July 2026JP MorganMaintainsNeutral$30 → $28
6 July 2026Cantor FitzgeraldReiteratesNeutral$27
6 July 2026Cantor FitzgeraldReiteratesNeutral—
6 July 2026HSBCDowngradeHold$32 → $28
6 July 2026HSBCDowngradeHold—
10 June 2026RBC CapitalUpgradeSector Perform—
29 Apr 2026CitigroupMaintainsNeutral—
20 Apr 2026RBC CapitalReiteratesUnderperform—
16 Apr 2026CICCInitiatesOutperform—
13 Apr 2026UBSMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PFE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PFE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Pfizer Inc. returned +11.2% against +17.3% for the S&P 500, dividends included.

PFE vs S&P 500, last 12 monthsTotal return, rebased to 100
9095100105110115120Jan 26Apr 26Jul 26Oct 26PFES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PFE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.5%
Analysts raising
2
Analysts cutting
0
Fundamentals

Pfizer Inc. (PFE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.6×

Cheaper than 21% of US stocks

Price / sales
2.5×

Cheaper than 46% of US stocks

Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
8.3×

Cheaper than 44% of US stocks

Growth & margins
Revenue growth (YoY)
2.6%

Higher than 33% of US stocks

Earnings growth (YoY)
2.6%

Higher than 39% of US stocks

Gross margin
72.8%

Higher than 85% of US stocks

Operating margin
27.9%

Higher than 86% of US stocks

Net margin
6.8%

Higher than 64% of US stocks

Returns & dividend
Return on equity
5.0%

Higher than 53% of US stocks

Return on assets
5.8%

Higher than 80% of US stocks

Dividend yield
6.2%

Higher than 94% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pfizer Inc. (PFE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pfizer Inc. has a market value of $158.5B and an enterprise value of $210.5B.

  • Revenue in the twelve months to 30 June 2026: $63.7B. The latest quarter grew 2.6% year on year.

  • Net income over the same four quarters: $4.4B, a 6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.76.

  • Free cash flow in the twelve months to 30 June 2026: $11.0B.

  • Pfizer Inc. spent $9.8B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 5.7B.

  • Trailing P/E: 36.6×; forward P/E: 9.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 6.19%, paying out 226% of earnings.

  • Pfizer Inc. employs 75,000 people — $849K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

PFE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
PFEPfizer Inc.$158.5B
82
GILDGilead Sciences, Inc.$179.1B
94
BMYBristol Myers Squibb Co.$121.3B
99
AMGNAmgen, Inc.$217.0B
93
MRKMerck & Co., Inc.$352.3B
83
ABBVAbbVie, Inc.$471.2B
96
JNJJohnson & Johnson$614.0B
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pfizer Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PFE news & analysis

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

PRNewsWire · 6 Oct 2026neutral

Astellas said it will present 21 oncology abstracts at ESMO 2026, covering several cancers. The announced research includes PADCEV plus pembrolizumab data in advanced bladder cancer and VYLOY research on CLDN18.2 in gastric cancer.

Why it matters — The announcement concerns Astellas’ oncology portfolio rather than Pfizer, so it offers no direct company-specific update for PFE watchers.

PFE vs. JNJ: Which Stock Is the Better Value Option?

Zacks Investment Research · 6 Oct 2026neutral

Zacks Investment Research compares Pfizer and Johnson & Johnson for investors considering value stocks in the Large Cap Pharmaceuticals sector. The excerpt poses the question of which offers better value but does not provide a conclusion.

Why it matters — The comparison raises a value-investing question relevant to investors following Pfizer, without stating which stock is the better value.

Are Investors Undervaluing Pfizer (PFE) Right Now?

Zacks Investment Research · 6 Oct 2026neutral

Zacks Investment Research says it focuses on its Zacks Rank system, which uses earnings estimates and estimate revisions, while also tracking value, growth, and momentum trends. The excerpt does not state whether Pfizer is undervalued.

Why it matters — PFE watchers should note that the excerpt describes Zacks’ evaluation approach but offers no Pfizer-specific conclusion.

Pfizer Declares Fourth-Quarter 2026 Dividend

Business Wire · 6 Oct 2026neutral

Pfizer’s board declared a fourth-quarter 2026 dividend of $0.43 per common share, payable December 7, 2026, to shareholders of record on November 6, 2026. The company said this will be its 352nd consecutive quarterly dividend.

Why it matters — PFE watchers may note the declared dividend amount and the company’s stated commitment to maintaining and, over the longer term, growing the dividend.

FAQ

Frequently asked questions about PFE stock

What is the PFE stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Pfizer Inc. have a median 12-month price target of $28, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PFE stock a buy right now?

Of the 28 analysts covering Pfizer Inc., 10 rate it a Buy, 16 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Pfizer Inc. 82 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PFE?

As at 6 Oct 2026, Pfizer Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will PFE stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +1.8% from the last close, and Ticker Nerd's factor model ranks Pfizer Inc. 82 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PFE stock forecast for 2030?

No analyst covering Pfizer Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PFE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.

How has PFE stock performed over the past year?

Pfizer Inc. returned +11.2% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pfizer Inc. do?

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide.

What is the latest news on PFE?

The most recent item we track (PRNewsWire, 6 Oct 2026): "Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026". Astellas said it will present 21 oncology abstracts at ESMO 2026, covering several cancers. The announced research includes PADCEV plus pembrolizumab data in advanced bladder cancer and VYLOY research on CLDN18.2 in gastric cancer.

Company

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems. Pfizer also maintains a consumer health presence through established over-the-counter and wellness products in select markets. The company plays a central role in global healthcare by supplying prescription therapies and immunizations across major therapeutic areas, while its research and development organization continues to support the launch, approval, and lifecycle management of new treatments. Founded in 1849 and headquartered in New York City, Pfizer Inc. remains one of the most recognized names in the pharmaceutical industry.

CEO Dr. Albert Bourla D.V.M., Ph.D. · 75,000 employees · United States · https://www.pfizer.com